Zobrazeno 1 - 10
of 143
pro vyhledávání: '"Mario, Masarone"'
Autor:
Marcello Dallio, Moris Sangineto, Mario Romeo, Marina Cipullo, Annachiara Coppola, Simone Mammone, Giuseppe Di Gioia, Mario Masarone, Marcello Persico, Gaetano Serviddio, Alessandro Federico
Publikováno v:
Nutrition & Diabetes, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Background Unhealthy lifestyles represent a key element fueling Non-alcoholic fatty liver disease (NAFLD) onset and worsening. We aimed to evaluate the effects of forced acute lifestyle changes on NAFLD evolution. Methods 187 NAFLD patients
Externí odkaz:
https://doaj.org/article/3b9d0526359c4eab9979f3277fddae76
Publikováno v:
Viruses, Vol 16, Iss 11, p 1792 (2024)
Hepatitis C is a disease for which in approximately 30 years we have gone from the discovery of the causative agent in 1989, to the introduction of direct-acting antiviral (DAAs) therapies starting from 2011, and to a proposal for its elimination in
Externí odkaz:
https://doaj.org/article/3e58def650fb417b8f7aa0671701cbb5
Publikováno v:
Viruses, Vol 15, Iss 11, p 2199 (2023)
HCV infection is still a major burden worldwide, and most countries are not on track to meet the WHO 2030 elimination goal. The current challenge is to identify individuals to be treated. In this study, we will describe the trend of new DAA prescript
Externí odkaz:
https://doaj.org/article/73f39e3936f040a482610e6a6aa0bef4
Autor:
Giuseppina Guarino, Felice Strollo, Peter Malfertheiner, Teresa Della Corte, Stefano Stagi, Mario Masarone, Sandro Gentile
Publikováno v:
Frontiers in Drug Safety and Regulation, Vol 2 (2022)
Introduction: Metabolic syndrome (MetS) is increasingly common in adults as well as in children and adolescents. However, preventing and treating MetS is one of the most pressing challenges for public health services worldwide. At present, the only a
Externí odkaz:
https://doaj.org/article/f2dc06e7303a4b3b8600b56c50bb7790
Publikováno v:
Exploration of Medicine, Vol 1, Iss 5, Pp 259-286 (2020)
Non-alcoholic fatty liver disease (NAFLD) has become the most common liver alteration worldwide. It encompasses a spectrum of disorders that range from simple steatosis to a progressive form, defined non-alcoholic steatohepatitis (NASH), that can lea
Externí odkaz:
https://doaj.org/article/58be8b6a3aff4f4e8c54d4d4a663e9eb
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is the definition recently proposed to better circumscribe the spectrum of conditions long known as non-alcoholic fatty liver disease (NAFLD) that range from simple steatosis without infl
Externí odkaz:
https://doaj.org/article/4cf8457c7b424ce6845b549cc6ec7289
Autor:
Marcello Dallio, Mario Masarone, Mario Romeo, Concetta Tuccillo, Filomena Morisco, Marcello Persico, Carmelina Loguercio, Alessandro Federico
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Introduction: PNPLA3, TM6SF2, and MBOAT7 genes play a crucial role in non-alcoholic fatty liver disease (NAFLD) development and worsening. However, few data are available on their treatment response influence. The aim of this trial is to explore the
Externí odkaz:
https://doaj.org/article/d3aa2818097d4237b0233d6ebc9d0bdd
Autor:
Mario Masarone, Emilia Vaccaro, Roberta Sciorio, Pietro Torre, Antonio Della Vecchia, Andrea Aglitti, Rita Caliulo, Anna Borrelli, Marcello Persico
Publikováno v:
BMJ Open, Vol 11, Iss 5 (2021)
Background The SARS-CoV-2 pandemic has infected millions of people and has caused more than 2.30 million deaths worldwide to date. Several doubts arise about the role of asymptomatic carriers in virus transmission. During the first epidemic outbreak
Externí odkaz:
https://doaj.org/article/25a381e151fd44f8aa1e528117e013fd
Autor:
Ersilia Satta, Felice Strollo, Luisa Borgia, Giuseppina Guarino, Carmine Romano, Mario Masarone, Sandro Gentile
Introduction: Patients with Type 1 and Type 2 diabetes mellitus (T1DM and T2DM) are at high risk of developing chronic kidney disease (CKD), i.e., diabetic nephropathy (DN), whose onset and progression are associated with a high morbidity and mortali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b104681ca2d5185467fff26e21212661
https://doi.org/10.21203/rs.3.rs-2801457/v1
https://doi.org/10.21203/rs.3.rs-2801457/v1
Autor:
Loreta A. Kondili, Maria Giovanna Quaranta, Luisa Cavalletto, Vincenza Calvaruso, Luigina Ferrigno, Roberta D'Ambrosio, Ilaria Simonelli, Giuseppina Brancaccio, Giovanni Raimondo, Maurizia R. Brunetto, Anna Linda Zignego, Carmine Coppola, Andrea Iannone, Elisa Biliotti, Gabriella Verucchi, Marco Massari, Anna Licata, Francesco Barbaro, Marcello Persico, Francesco Paolo Russo, Filomena Morisco, Maurizio Pompili, Mauro Viganò, Massimo Puoti, Teresa Santantonio, Erica Villa, Antonio Craxì, Liliana Chemello, Valentina Panetta, Giovanni Battista Gaeta, Roberto Filomia, Barbara Coco, Monica Monti, Daniela Caterina Amoruso, Salvatore Madonia, Donatella Ieluzzi, Gloria Taliani, Lorenzo Badia, Guglielmo Marco Migliorino, Alessia Giorgini, Mario Masarone, Pierluigi Blanc, Valentina Cossiga, Martina De Siena, Xhimi Tata, Maria Grazia Rumi, Luchino Chessa, Pietro Lampertico, Carlo Ferrari, Ivan Gentile, Giustino Parruti, Leonardo Baiocchi, Alessia Ciancio, Pietro Invernizzi, Alessandro Federico, Carlo Torti, Giulia Morsica, Pietro Andreone, Alessio Aghemo, Patrizia Popoli, Stefano Vella
Background and aims: Severe liver disease markers assessed before HCV eradication are acknowledged to usually improve after the SVR. We prospectively evaluated, in the PITER cohort, the long-term HCC risk profile based on predictors monitored after H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::438d10f671907a94a75ee1d3ee7309a9
https://hdl.handle.net/2108/319297
https://hdl.handle.net/2108/319297